164 related articles for article (PubMed ID: 38387107)
1. Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection.
Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL
Neoplasia; 2024 Apr; 50():100979. PubMed ID: 38387107
[TBL] [Abstract][Full Text] [Related]
2. Integrating IASLC grading and radiomics for predicting postoperative outcomes in stage IA invasive lung adenocarcinoma.
Chen Y; Wu J; You J; Gao M; Lu S; Sun C; Shu Y; Wang X
Med Phys; 2024 May; ():. PubMed ID: 38781536
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis.
Zhao K; Yang L; Liu L; Wang G; Zhang J; Gao X; Guo C; Huang C; Chen Y; Li S
BMC Surg; 2024 May; 24(1):140. PubMed ID: 38720305
[TBL] [Abstract][Full Text] [Related]
4. Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB-IIA Lung Adenocarcinoma.
Zhai W; Gong L; Zheng Y; Yan Q; Lai R; Liang D; Wong W; Dai S; Wang J
Front Oncol; 2022; 12():851276. PubMed ID: 35402251
[TBL] [Abstract][Full Text] [Related]
5. Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study.
Chen D; Wang X; Zhang F; Han R; Ding Q; Xu X; Shu J; Ye F; Shi L; Mao Y; Chen Y; Chen C
Ther Adv Med Oncol; 2020; 12():1758835920978147. PubMed ID: 33403018
[TBL] [Abstract][Full Text] [Related]
6. High-Risk Features Associated with Recurrence in Stage I Lung Adenocarcinoma.
Fick CN; Dunne EG; Vanstraelen S; Toumbacaris N; Tan KS; Rocco G; Molena D; Huang J; Park BJ; Rekhtman N; Travis WD; Chaft JE; Bott MJ; Rusch VW; Adusumilli PS; Sihag S; Isbell JM; Jones DR
J Thorac Cardiovasc Surg; 2024 May; ():. PubMed ID: 38788834
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components.
Li R; Qiu J; Li Z; Li H; Tang Z; Yu W; Tian H; Sun Z
World J Surg Oncol; 2024 Jan; 22(1):32. PubMed ID: 38273367
[TBL] [Abstract][Full Text] [Related]
8. Beneficial implications of adjuvant chemotherapy for stage IB lung adenocarcinoma exhibiting elevated SUVmax in FDG-PET/CT: a retrospective study from a single center.
Huang M; Liu B; Li X; Li N; Yang X; Wang Y; Zhang S; Lu F; Li S; Yan S; Wu N
Front Oncol; 2024; 14():1367200. PubMed ID: 38529383
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.
She Y; Li S; Deng J; Ren Y; Zhao M; Zhong Y; He Y; Chen Q; Zhao D; Zhu Y; Hou L; Wu C; Xie D; Chen C
Eur J Cancer; 2022 Dec; 177():53-62. PubMed ID: 36323053
[TBL] [Abstract][Full Text] [Related]
10. A Novel Radiopathological Grading System to Tailor Recurrence Risk for Pathologic Stage IA Lung Adenocarcinoma.
Qiu ZB; Wang MM; Yan JH; Zhang C; Wu YL; Zhang S; Zhong WZ;
Semin Thorac Cardiovasc Surg; 2023 Autumn; 35(3):594-602. PubMed ID: 35709883
[TBL] [Abstract][Full Text] [Related]
11. The IASLC Proposed Grading System Accurately Predicts Prognosis and Mediastinal Nodal Metastasis in Patients With Clinical Stage I Lung Adenocarcinoma.
Xu L; Su H; Hou L; Wang F; Xie H; She Y; Gao J; Zhao S; Dai C; Xie D; Zhu Y; Wu C; Zhao D; Chen C;
Am J Surg Pathol; 2022 Dec; 46(12):1633-1641. PubMed ID: 36224092
[TBL] [Abstract][Full Text] [Related]
12. Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma.
Woo W; Cha YJ; Kim BJ; Moon DH; Lee S
Clin Lung Cancer; 2022 Nov; 23(7):e435-e442. PubMed ID: 35945128
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma.
Xu CH; Wang W; Wei Y; Hu HD; Zou J; Yan J; Yu LK; Yang RS; Wang Y
Eur J Surg Oncol; 2015 Oct; 41(10):1430-6. PubMed ID: 26123994
[TBL] [Abstract][Full Text] [Related]
14. A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma.
Wang K; Liu X; Ding Y; Sun S; Li J; Geng H; Xu M; Wang M; Li X; Sun D
BMC Pulm Med; 2023 Oct; 23(1):377. PubMed ID: 37805451
[TBL] [Abstract][Full Text] [Related]
15. Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma.
Xie D; Wang TT; Huang SJ; Deng JJ; Ren YJ; Yang Y; Wu JQ; Zhang L; Fei K; Sun XW; She YL; Chen C
Transl Lung Cancer Res; 2020 Aug; 9(4):1112-1123. PubMed ID: 32953490
[TBL] [Abstract][Full Text] [Related]
16. BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
Bucciarelli PR; Tan KS; Chudgar NP; Brandt W; Montecalvo J; Eguchi T; Liu Y; Aly R; Travis WD; Adusumilli PS; Jones DR
J Thorac Oncol; 2018 Jan; 13(1):73-84. PubMed ID: 29097253
[TBL] [Abstract][Full Text] [Related]
17. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.
Yoshizawa A; Motoi N; Riely GJ; Sima CS; Gerald WL; Kris MG; Park BJ; Rusch VW; Travis WD
Mod Pathol; 2011 May; 24(5):653-64. PubMed ID: 21252858
[TBL] [Abstract][Full Text] [Related]
18. Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces.
Lv Y; Li S; Liu Z; Ren Z; Zhao J; Tao G; Zheng Z; Han Y; Ye B
Lung Cancer; 2023 Mar; 177():51-58. PubMed ID: 36736075
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma.
Zhao ZR; Xi SY; Li W; Situ DR; Chen KM; Yang H; Su XD; Lin YB; Long H
Lung Cancer; 2015 Dec; 90(3):604-9. PubMed ID: 26547801
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of postoperative folate receptor-positive circulating tumor cells (FR + CTCs) for long-term prognosis in patients with invasive adenocarcinoma (IAC) of the lung.
Ma Z; Zhou Z; Wang S; Ji H; Zhao D; Wang L; Chen J
Thorac Cancer; 2024 May; 15(13):1060-1071. PubMed ID: 38532562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
